Examples of using Sofosbuvir in English and their translations into Polish
{-}
-
Colloquial
-
Official
-
Medicine
-
Ecclesiastic
-
Ecclesiastic
-
Financial
-
Official/political
-
Programming
-
Computer
Sovaldi contains the active substance sofosbuvir which is given to treat hepatitis C virus infection in adults of 18 years and older.
may decrease sofosbuvir plasma concentration leading to reduced therapeutic effect of Sovaldi.
The most common adverse drug reactions occurring in subjects receiving sofosbuvir and ribavirin or sofosbuvir, ribavirin and peginterferon alfa were fatigue,
No dose adjustment of sofosbuvir or ciclosporin is required when sofosbuvir and ciclosporin are used concomitantly.
Regarding the risk of bradycardia, further analyses indicated that this risk can occur when sofosbuvir is given with another direct-acting antiviral and amiodarone.
The concomitant use of amiodarone was limited through the clinical development of sofosbuvir plus DAAs.
The safety of tenofovir disoproxil fumarate in the setting of ledipasvir/sofosbuvir and a pharmacokinetic enhancer has not been established.
The safety of tenofovir disoproxil fumarate when co-administered with ledipasvir/sofosbuvir and a pharmacokinetic enhancer has not been established.
Relative to healthy subjects(n 284), the sofosbuvir and GS-331007 AUC0-24 was 57% higher
Sofosbuvir and GS-331007 AUCs are near dose proportional over the dose range of 200 mg to 400 mg.
If sofosbuvir is used in combination with peginterferon alfa,
Sofosbuvir is approximately 85% bound to human plasma proteins(ex vivo data)
Na osnovnoj listi su evolokumab za liječenje hiperkolesterolemije, sofosbuvir combination++ velpatasvir voksilaprevir to treat chronic hepatitis C., Vandetanib for treatment of thyroid cancer, Eculizumab for the
Sofosbuvir was fully active against substitutions associated with resistance to other direct-acting antivirals with different mechanisms of actions, such as NS5B non-nucleoside inhibitors, NS3 protease inhibitors
The primary list are for the treatment of hypercholesterolemia evolokumab, sofosbuvir combination++ velpatasvir voksilaprevir to treat chronic hepatitis C., Vandetanib for treatment of thyroid cancer, Eculizumab for the treatment of hemolytic uremic syndrome,
Co-administration of Sovaldi with medicinal products that inhibit P-gp and/or BCRP may increase sofosbuvir plasma concentration without increasing GS-331007 plasma concentration,
Co-administration of tenofovir disoproxil fumarate with ledipasvir/sofosbuvir has been shown to increase plasma concentrations of tenofovir,
meeting the MILAN criteria received 400 mg sofosbuvir and 1,000-1,200 mg ribavirin daily for a maximum of 24 weeks,
ledipasvir/sofosbuvir and atazanavir/ritonavir may increase adverse reactions related to tenofovir disoproxil fumarate,
Relative to subjects with normal hepatic function, the sofosbuvir AUC0-24 was 126%